Novo Nordisk is actually the best at helping you lose weight

Summary

• The post is a satirical joke about the high valuation of Novo Nordisk (NVO), the maker of weight-loss drugs like Ozempic and Wegovy.
• The author's "thesis" is a punchline: the stock is so expensive that buying it will leave an investor with no money for food, thus causing weight loss. This is a commentary on the stock's potentially overstretched valuation.
• Quality assessment: This is noise. It is a low-effort joke post, not a piece of financial analysis or due diligence.